VRTX Vertex Pharmaceuticals Inc

Price (delayed)

$183.49

Market cap

$47.6B

P/E Ratio

23.89

Dividend/share

N/A

EPS

$7.68

Enterprise value

$42.43B

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather ...

Highlights
The price to earnings (P/E) is 66% less than the 5-year quarterly average of 70.6
The gross profit has grown by 24% YoY and by 4% from the previous quarter
VRTX's debt has soared by 71% YoY
The EPS has declined by 28% since the previous quarter and by 4.2% year-on-year

Key stats

What are the main financial stats of VRTX
Market
Shares outstanding
259.43M
Market cap
$47.6B
Enterprise value
$42.43B
Valuations
Price to earnings (P/E)
23.89
Price to book (P/B)
5.16
Price to sales (P/S)
7.11
EV/EBIT
17.16
EV/EBITDA
16.39
EV/Sales
6.35
Earnings
Revenue
$6.68B
EBIT
$2.47B
EBITDA
$2.59B
Free cash flow
$1.78B
Per share
EPS
$7.68
Free cash flow per share
$6.86
Book value per share
$35.53
Revenue per share
$25.81
TBVPS
$41.78
Balance sheet
Total assets
$12.22B
Total liabilities
$3.03B
Debt
$893.85M
Equity
$9.2B
Working capital
$6.62B
Liquidity
Debt to equity
0.1
Current ratio
4.61
Quick ratio
4.16
Net debt/EBITDA
-2
Margins
EBITDA margin
38.7%
Gross margin
87.9%
Net margin
29.8%
Operating margin
33.9%
Efficiency
Return on assets
16.8%
Return on equity
22.8%
Return on invested capital
72.5%
Return on capital employed
23.8%
Return on sales
37%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VRTX stock price

How has the Vertex Pharmaceuticals stock price performed over time
Intraday
-0.07%
1 week
-1.17%
1 month
-8.22%
1 year
-31.58%
YTD
-22.36%
QTD
-9%

Financial performance

How have Vertex Pharmaceuticals's revenue and profit performed over time
Revenue
$6.68B
Gross profit
$5.87B
Operating income
$2.27B
Net income
$1.99B
Gross margin
87.9%
Net margin
29.8%
VRTX's net margin is down by 31% QoQ and by 23% YoY
The operating margin has decreased by 28% QoQ and by 13% YoY
Vertex Pharmaceuticals's net income has decreased by 28% QoQ and by 4.3% YoY
The operating income has declined by 25% since the previous quarter but it has grown by 8% year-on-year

Growth

What is Vertex Pharmaceuticals's growth rate over time

Valuation

What is Vertex Pharmaceuticals stock price valuation
P/E
23.89
P/B
5.16
P/S
7.11
EV/EBIT
17.16
EV/EBITDA
16.39
EV/Sales
6.35
The price to earnings (P/E) is 66% less than the 5-year quarterly average of 70.6
The EPS has declined by 28% since the previous quarter and by 4.2% year-on-year
The stock's price to book (P/B) is 60% less than its 5-year quarterly average of 12.9 and 25% less than its last 4 quarters average of 6.9
The equity has grown by 22% YoY and by 2.4% from the previous quarter
The price to sales (P/S) is 47% less than the 5-year quarterly average of 13.3 and 26% less than the last 4 quarters average of 9.6
VRTX's revenue is up by 24% YoY and by 4.2% QoQ

Efficiency

How efficient is Vertex Pharmaceuticals business performance
The return on invested capital has declined by 32% since the previous quarter and by 8% year-on-year
VRTX's return on assets is down by 31% since the previous quarter and by 29% year-on-year
The return on equity has declined by 31% since the previous quarter and by 31% year-on-year
The return on sales has declined by 29% since the previous quarter and by 13% year-on-year

Dividends

What is VRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VRTX.

Financial health

How did Vertex Pharmaceuticals financials performed over time
Vertex Pharmaceuticals's current ratio has increased by 24% YoY and by 5% from the previous quarter
Vertex Pharmaceuticals's total assets has increased by 20% YoY
VRTX's debt is 90% lower than its equity
VRTX's debt has soared by 71% YoY
The debt to equity rose by 43% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.